MASHINIi

IO Biotech, Inc..

IOBT.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products

IO Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-oncology therapies. The company's primary focus is on developing cancer immunotherapies based on its T-win® technology platform. This platform is designed to activate T cells to target and kill cancer cells. ...Show More

Ethical Profile

Mixed.

IO Biotech focuses on developing immune-modulating cancer vaccines, with a lead candidate in Phase 3 trials for melanoma and Phase 2 for lung, head, and neck cancers, directly addressing major health challenges. However, reports suggest potential tensions regarding fair pricing if treatments become inaccessible. As a biopharmaceutical company, its drug development process likely involves animal testing, though specific policies to minimize use are not publicly detailed. Transparency on pay ratios and worker conditions is limited, typical for smaller biotech firms. The integrity of clinical trial data and regulatory compliance are critical for honest business practices. Information on environmental impact, ethical sourcing, or waste reduction initiatives is not publicly available.

Value Scores

Better Health for All0
-100100
Fair Money & Economic Opportunity0
-100100
Fair Pay & Worker Respect0
-100100
Fair Trade & Ethical Sourcing0
-100100
Honest & Fair Business0
-100100
Kind to Animals0
-100100
No War, No Weapons0
-100100
Planet-Friendly Business0
-100100
Respect for Cultures & Communities0
-100100
Safe & Smart Tech0
-100100
Zero Waste & Sustainable Products0
-100100

Better Health for All

0

No evidence available to assess IO Biotech, Inc. on Better Health for All.

Fair Money & Economic Opportunity

0

IO Biotech, Inc. is a clinical-stage biopharmaceutical company focused on developing immune-oncology therapies through research, development, and clinical trials. The company's core business does not involve lending, insuring, moving, or storing money for consumers.

1
Therefore, all KPIs related to fair money and economic opportunity, which are designed to assess financial institutions and their consumer-facing financial products or services, are not applicable to IO Biotech, Inc.

Fair Pay & Worker Respect

0

No specific, quantifiable data was found in the provided articles for any of the KPIs under the 'Fair Pay & Worker Respect' value. The articles primarily discuss IO Biotech's workforce reductions, including laying off 34 workers in September 2025 and an approximate 50% downsizing (around 39 people) effective October 1, 2026, based on 78 full-time employees as of June 30, 2025.

1
The company expects to incur $2.4 million to $2.6 million in one-time costs, primarily for severance fees and other employee benefits related to these layoffs.
2
However, this information does not directly map to the quantitative thresholds of the defined KPIs, such as living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, voluntary turnover rate, labor violation incidents, insecure contract share, or health insurance coverage.

Fair Trade & Ethical Sourcing

0

No evidence available to assess IO Biotech, Inc. on Fair Trade & Ethical Sourcing.

Honest & Fair Business

0

No evidence available to assess IO Biotech, Inc. on Honest & Fair Business.

Kind to Animals

0

No specific, concrete evidence was found in the provided articles to assess IO Biotech, Inc. against any of the 'Kind to Animals' KPIs. The articles discuss general industry trends and regulatory changes by the FDA regarding animal testing, but do not provide specific data points or actions taken by IO Biotech, Inc. itself regarding cruelty-free certifications, alternative testing usage, humane certifications, wildlife conservation, ethical input substitution, supplier audits, cage-free sourcing, animal testing policy or volume, innovation investment, animal agriculture ethics, animal-free R&D collaboration, or public policy engagement related to animal welfare.

1

No War, No Weapons

0

No specific, concrete evidence was found in the provided articles regarding IO Biotech, Inc.'s involvement in arms manufacturing, military contracts, dual-use technologies, or any related activities. The articles discuss general industry export controls

1
and a new Pentagon program for biotechnology firms
2
, but do not provide any direct information or metrics pertaining to IO Biotech, Inc.'s operations, revenue, or policies concerning war, weapons, or peacebuilding initiatives.

Planet-Friendly Business

0

No quantitative or qualitative data relevant to the 'Planet-Friendly Business' ethical value was found in the provided articles for IO Biotech, Inc.

1
Therefore, no KPIs could be scored.

Respect for Cultures & Communities

0

No evidence available to assess IO Biotech, Inc. on Respect for Cultures & Communities.

Safe & Smart Tech

0

IO Biotech's Privacy Notice (last updated October 23, 2024) and Privacy Policy (last updated January 2024) outline that individuals have rights to access, correct, delete, restrict processing of, object to processing of, withdraw consent for, and request data portability for their Personal Information.

1
These are good user privacy controls. The company states it retains Personal Information as long as needed for a legitimate business purpose, based on criteria such as service provision, type of information, and legal/contractual obligations, which represents standard data retention practices.
2
There are no documented incidents of unauthorized data use. The company also states it uses data transfer agreements, such as Standard Contractual Clauses, for international data transfers from the EEA/UK to the US, and processes data based on GDPR articles including legitimate interest, consent, contract performance, and legal obligation, indicating good compliance with applicable regulations.
3

Zero Waste & Sustainable Products

0

No specific quantitative data for IOBT.US was found across any of the KPIs related to Zero Waste & Sustainable Products.

1
The available articles discuss general industry trends and initiatives by other companies but do not provide any measurable facts about IOBT.US's performance in areas such as waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero-waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
2

Own IO Biotech, Inc.?

Upload your portfolio and see how all your holdings score across 11 ethical dimensions.

Audit My Portfolio

AI-generated analysis based on publicly available data. Not financial advice. Ratings are expressions of opinion derived from automated models and may contain inaccuracies. See our Risk Disclosure for full details.